EGFR / ErbB-2抑制剂是细胞可渗透的4-苯胺基喹唑啉化合物，其是EGFR和c-erbB2的有效，可逆和ATP竞争性抑制剂（分别为IC | 50 | = 20 nM和79 nM），成员参与乳腺癌发展和进程的I型生长因子受体家族。已显示可有效抑制过度表达EGRF或Neu（c-erbB-2）的肿瘤细胞的增殖（IC | 50 |〜1.2-2.5μM）。 EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM & 79 nM, respectively), members of the type I growth factor receptor family that is involved in breast cancer development and progression. Shown to effectively inhibit the proliferation (IC|50|~ 1.2-2.5 μM) of tumor cells overexpressing EGRF or Neu (c-erbB-2).